HLA-A*1101 KRAS G12D 蛋白, Human (HEK293, His-Avi)

HLA-A*1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A*1101 KRAS G12D Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A*1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVVGADGVGK peptide. HLA-A*1101 KRAS G12D Protein, Human (HEK293, His-Avi), has molecular weight of 51-60 kDa.

HLA-A*1101 是一种抗原呈递主要组织相容性复合物 I 类 (MHCI) 分子，通过在抗原呈递细胞上主要呈递病毒和肿瘤衍生肽，在免疫反应中发挥关键作用。这种呈现促进 HLA-A 限制性 CD8 阳性 T 细胞上的 α-β T 细胞受体 (TCR) 识别这些肽，引导旨在消除感染或转化细胞的抗原特异性 T 细胞免疫反应。与 B2M/beta 2 微球蛋白合作，HLA-A*1101 显示出多种肽库，包括病毒表位和肿瘤相关抗原。所呈现的肽和 MHCI 分子都有助于抗原识别的特异性，肽决定精细特异性，而 MHCI 残基影响 T 细胞的 MHC 限制。HLA-A*1101 通常呈递由胞质蛋白水解产生的 8 至 13 个氨基酸的细胞内肽抗原。它可以结合含有等位基因特异性结合基序的不同肽，主要由位置 2 和 9 处的锚定残基定义。等位基因特异性基序表征不同的肽库，例如 A*01:01，以共同的规范呈现病毒表位和肿瘤抗原主题。值得注意的是，HLA-A*1101 无法呈递来自 EBV 潜伏抗原的高免疫原性肽。对于 A*11:01，它在控制感染、呈现 HIV-1、EBV 和 HBV 的免疫显性表位以及促进针对 SARS-CoV-2 的免疫反应方面发挥着至关重要的作用。

Human

HEK293

C-Avi;C-His

AAV53343 (G25-T305)&P61769 (I21-M119)&VVVGADGVGK

3105  [NCBI]&567  [NCBI]

51-60 kDa

Greater than 95% as determined by Tris-Bis PAGE.

无菌粉末.

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Normally 8% trehalose is added as protectant before lyophilization.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.